CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Vaporized Marijuana +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03705559
NCT03705559Phase 1Completed
CompareCT.gov

Interactions of Marijuana and Opioids: Pharmacodynamic Effects

Shanna Babalonis, PhD·interventional·Posted Oct 15, 2018·Updated Apr 10, 2025

In Brief

A Phase 1 clinical trial evaluating Vaporized Marijuana, Opioid Agonist, and 1 other intervention for Marijuana Usage and Opioid Use. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Usage, Opioid Use
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 15, 2018
Enrollment StartJun 21, 2019
Primary CompletionFeb 15, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 7.7 years ago

Interventions

Vaporized Marijuanadrug

Active Marijuana administered through vaporizer

Opioid Agonistdrug

Active Opioid Agonist administered intranasally

Placebodrug

Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)